Kubota Pharmaceutical Holdings Past Earnings Performance
Past criteria checks 0/6
Kubota Pharmaceutical Holdings has been growing earnings at an average annual rate of 13.3%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 27.9% per year.
Key information
13.3%
Earnings growth rate
18.7%
EPS growth rate
Pharmaceuticals Industry Growth | 3.4% |
Revenue growth rate | 27.9% |
Return on equity | -56.3% |
Net Margin | -3,817.9% |
Next Earnings Update | 14 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Kubota Pharmaceutical Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 39 | -1,489 | 633 | 788 |
30 Sep 23 | 36 | -1,362 | 648 | 790 |
30 Jun 23 | 25 | -1,563 | 649 | 1,051 |
31 Mar 23 | 13 | -1,804 | 628 | 1,290 |
31 Dec 22 | 8 | -2,015 | 602 | 1,512 |
30 Sep 22 | 2 | -2,366 | 558 | 1,845 |
30 Jun 22 | 0 | -2,462 | 529 | 1,952 |
31 Mar 22 | 0 | -2,575 | 571 | 2,032 |
31 Dec 21 | 0 | -2,616 | 604 | 2,040 |
30 Sep 21 | 0 | -2,496 | 606 | 1,943 |
30 Jun 21 | 0 | -2,534 | 635 | 1,949 |
31 Mar 21 | 37 | -2,420 | 626 | 1,898 |
31 Dec 20 | 37 | -2,437 | 607 | 1,972 |
30 Sep 20 | 37 | -2,679 | 603 | 2,275 |
30 Jun 20 | 37 | -2,896 | 592 | 2,496 |
31 Mar 20 | 0 | -3,083 | 567 | 2,712 |
31 Dec 19 | 0 | -3,065 | 532 | 2,756 |
30 Sep 19 | 0 | -3,121 | 611 | 2,729 |
30 Jun 19 | 0 | -3,084 | 660 | 2,655 |
31 Mar 19 | 0 | -3,045 | 718 | 2,554 |
31 Dec 18 | 0 | -3,046 | 794 | 2,479 |
30 Sep 18 | 0 | -2,832 | 794 | 2,244 |
30 Jun 18 | 0 | -2,842 | 878 | 2,602 |
31 Mar 18 | 0 | -3,102 | 1,028 | 2,058 |
31 Dec 17 | 0 | -3,444 | 1,240 | 2,379 |
30 Sep 17 | 39 | -3,516 | 1,503 | 1,868 |
30 Jun 17 | 109 | -3,472 | 1,642 | 1,213 |
31 Mar 17 | 415 | -3,349 | 2,003 | 1,205 |
31 Dec 16 | 889 | -4,035 | 2,290 | 1,066 |
30 Sep 16 | 1,075 | -4,004 | 861 | 1,093 |
30 Jun 16 | 1,738 | -3,607 | 694 | 766 |
31 Mar 16 | 2,327 | -3,963 | 1,211 | 812 |
31 Dec 15 | 2,893 | -3,066 | 1,321 | 189 |
30 Sep 15 | 3,493 | -2,134 | 2,670 | 177 |
30 Jun 15 | 3,689 | -1,933 | 2,716 | 159 |
31 Mar 15 | 3,847 | -720 | 1,578 | 144 |
31 Dec 14 | 4,241 | -240 | 1,198 | 126 |
30 Sep 14 | 4,279 | -178 | 888 | 157 |
30 Jun 14 | 4,616 | 30 | 811 | 185 |
31 Mar 14 | 4,891 | 22 | 904 | 223 |
31 Dec 13 | 5,567 | 122 | 899 | 269 |
30 Sep 13 | 5,199 | 137 | 938 | 247 |
30 Jun 13 | 5,376 | 195 | 929 | 244 |
Quality Earnings: 4596 is currently unprofitable.
Growing Profit Margin: 4596 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4596 is unprofitable, but has reduced losses over the past 5 years at a rate of 13.3% per year.
Accelerating Growth: Unable to compare 4596's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4596 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (0.6%).
Return on Equity
High ROE: 4596 has a negative Return on Equity (-56.25%), as it is currently unprofitable.